Admac Lifesciences is a finished-dose manufacturer. It appears in 22 regulatory filings across 4 regulators, without an active US DMF or CEP on file. Its filings concentrate with ARCSA (EC), MINSA (CR) and DIGEMAPS (DO). Its GMP standing is certified by NAFDAC (NG). Customs aggregates show $1.9M of exports covering 203 molecules to 10 destinations in 2025.
| Regulator | Filings | GMP certificates |
|---|---|---|
| ARCSA (EC) | 13 | None |
| MINSA (CR) | 5 | None |
| DIGEMAPS (DO) | 3 | None |
| NAFDAC (NG) | 1 | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $330K | 7 |
| 2025 | Not reported | $1.9M | 10 |
| 2024 | Not reported | $1.3M | 9 |
| 2023 | Not reported | $790K | 5 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Beyond the filing counts above, the public registers hold no plant, inspection or portfolio detail for this company as at 9 July 2026. We report that as a gap rather than inferring an answer.
Choose your molecules and target markets. Admac Lifesciences comes back tiered against every other supplier able to file there.
Start for free